Strongbridge biopharma plc (SBBP)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Cash flows from operating activities:
Net loss

-43,715

-49,451

43,585

36,816

42,140

31,851

-70,953

-85,454

-112,721

-113,483

-110,735

-83,293

-65,999

-48,719

-43,169

-45,217

-49,464

-43,633

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of warrant liability

-13,786

-11,386

-9,968

-13,897

-24,217

-16,337

-14,424

-9,246

24,990

30,218

0

0

0

-

-

-

-

-

-

-

-

Stock-based compensation

8,025

8,597

9,088

9,029

8,442

7,807

7,092

6,307

5,686

5,167

4,949

4,721

4,447

4,606

4,139

3,539

5,231

3,940

0

0

0

Amortization of intangible asset

5,022

5,022

5,436

6,057

6,674

7,187

6,772

6,152

5,535

5,022

0

0

0

-

-

-

-

-

-

-

-

Accretion of discounts on marketable securities

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest and related guarantee fees paid in kind

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of debt discounts and debt issuance costs

-

-

-

-

-

1,484

1,220

897

656

482

0

0

0

-

-

-

-

-

-

-

-

Loss on extinguishment of debt

-

-

-

-

-

-21,549

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Deferred income tax expense

-

-

-

-

-

-

-

-

-

1,958

0

0

0

-

-

-

-

-

-

-

-

Deferred income tax expense (benefit)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,070

-1,199

-450

-450

0

0

0

Depreciation

80

77

74

72

61

46

30

15

10

10

10

10

10

10

11

10

12

11

0

0

0

Impairment/loss on investment in Antisense Therapeutics

-

-

-

-

-

-

-

-

-

-

-

-

-

550

0

0

0

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

-1,226

663

820

3,967

1,900

42

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Inventory

-2,368

-1,618

-3,525

2,369

2,936

3,437

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

-1,648

-3,079

-263

-624

951

3,028

655

1,215

813

444

-22

156

-642

-848

106

-1,248

1,169

1,165

0

0

0

Accrued liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

0

Other assets

-678

798

970

1,153

1,154

-381

-82

17

210

536

1,256

1,064

-367

88

0

0

0

-

-

-

0

Accounts payable

3,568

2,153

-1,266

-942

-445

-63

1,805

1,211

288

158

412

-764

577

-1,702

-3,487

-6,155

-84

1,737

0

0

0

Accrued and other liabilities

-6,397

-2,647

-12,288

-7,900

-1,200

-1,142

8,070

2,496

-599

3,043

0

0

0

-

-

-

-

-

-

-

-

Net cash used in operating activities

-41,716

-44,784

-75,639

-88,439

-84,865

-84,576

-62,750

-52,561

-54,066

-45,336

-41,422

-39,298

-31,708

-31,714

-34,600

-39,434

-42,107

-37,360

0

0

0

Cash flows from investing activities:
Payment for acquisitions

-

-

-

-

-

24,655

24,655

24,655

24,655

7,500

0

0

0

-

-

-

-

-

-

-

-

Purchases of property and equipment

-

74

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Maturities of marketable securities

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

25

0

0

0

Net cash provided by (used in) investing activities

-5,916

-20,761

159,253

159,262

158,970

134,330

-24,965

-24,965

-24,655

-7,500

0

0

0

-

-

-

-

-4,294

0

0

0

Cash flows from financing activities:
Proceeds from long-term debt, net

-

-

-

-

-

44,930

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Payment for loss on extinguishment of debt

-

-

-

-

-

9,990

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of ordinary shares, net

-

-

-

-

-

33,508

0

0

0

-

-

-

-

-

-

-

-

-

0

0

0

Proceeds from exercise of stock options

-

179

196

217

203

96

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Payments related to tax withholding for net-share settled equity awards

133

92

124

91

72

473

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Payment for amendment of long-term debt

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

Net cash (used in) provided by financing activities

-120

87

-71,389

-70,170

-62,204

15,226

110,732

129,176

121,228

43,509

0

0

0

-

-

-

-

77,404

0

0

0

Net decrease in cash and cash equivalents

-47,752

-65,458

12,225

653

11,901

64,980

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Effect of exchange rate changes on cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,139

241

0

0

0

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

7,591

-

-17,463

-20,503

6,392

35,991

0

0

0

Supplemental disclosures of cash flow information: Cash paid during the year for:
Interest

-

-

-

-

-

11,122

0

0

0

-

-

0

0

-

-

-

-

-

-

-

-

Income taxes other, net of refunds

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

Supplemental non-cash financing activities:
Changes in unrealized gain on marketable securities

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-